Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

Diabetes, Obesity and Metabolism

Volumn 12, Issue 10, 2010, Pages 891-899

  Porter, D W ^a   Kerr, B D ^a   Flatt, P R ^a   Holscher, C ^a   Gault, V A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cognitive function; GLP 1; Insulin resistance; Liraglutide; LTP; Obesity

Indexed keywords

GLUCOSE; INSULIN; LIRAGLUTIDE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CALORIC INTAKE; COGNITION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HIPPOCAMPUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEARNING; LIPID DIET; LONG TERM POTENTIATION; MALE; MEMORY; METABOLIC PARAMETERS; MOUSE; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; OBESITY; RECOGNITION; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 77956134398     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01259.x     Document Type: Article

References (41)

1. Knudsen LB, Nielsen PF, Huusfeldt PO. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once-daily administration. J Med Chem 2001, 43:1664-1669..
2. Agersø H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharmacol 2003, 19:141-150..
3. Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 2004, 47:4128-4134..
4. Vilsbøll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009, 11:11-18..
5. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269..
6. Rolin B, Larsen MO, Gotfredsen CF. The long-acting GLP-1 derivative NN2211 ameliorates glycaemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002, 283:745-752..
7. Bregenholt S, Møldrup A, Blume N. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005, 330:577-584..
8. Flatt PR, Bailey CJ, Green BD. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab 2009, 10:125-137..
9. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain-barrier. J Mol Neurosci 2002, 18:7-14..
10. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27:313-318..
11. McClean PL, Gault VA, Harriott P, Hölscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010, 630:158-162..
12. During MJ, Cao L, Zuzga DS. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179..
13. Hamilton A, Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166..
14. Alvarez E, Martínez MD, Roncero I. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005, 92:798-806..
15. Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009, 205:265-271..
16. Gault VA, Hölscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008, 587:112-117..
17. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39..
18. Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain 2006, 129:1659-1673..
19. Hölscher C, Gengler S, Gault VA, Harriott P, Mallot HA. Soluble beta-amyoid [25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 2007, 56:85-90..
20. Gengler S, Gault VA, Harriott P, Hölscher C. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid [25-35] are dependent on stimulation-protocol and genetic background. Exp Brain Res 2007, 179:621-630..
21. Stevens JF. Determination of glucose by an automated analyser. Clin Chem Acta 1971, 32:199-201..
22. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20:573-577..
23. Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007, 31:673-704..
24. Hölscher C, Anwyl R, Rowan MJ. Stimulation on the positive phase of hippocampal theta rhythm induces long-term potentiation which can be depotentiated by stimulation on the negative phase in area CA1 in vivo. J Neurosci 1997, 17:6470-6477..
25. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157..
26. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009, 94:1843-1852..
27. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose tolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007, 50:1752-1762..
28. Davis HR, Mullins DE, Pines JM. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obes Res 1998, 6:147-156..
29. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50:2530-2539..
30. Ernst MB, Wunderlich CM, Hess S. Enhanced Stat3 activation in POMC neurons provokes negative feedback inhibition of leptin and insulin signalling in obesity. J Neurosci 2009, 29:11582-11593..
31. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000, 23:542-549..
32. Trudeau F, Gagnon S, Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur J Pharmacol 2004, 490:177-186..
33. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychologial observations in Alzheimer's disease. Eur J Pharmacol 2004, 490:97-113..
34. Strachan MW. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem Soc Trans 2005, 33:1037-1040..
35. Iwai T, Suzuki M, Kobayashi K, Mori K, Mogi Y, Oka JI. The influences of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. Neurosci Res 2009, 64:67-74..
36. van der Heide LP, Kamal A, Artola A, Gispen WH, Ramakers GM. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. J Neurosci 2005, 94:1158-1166..
37. 8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice., [Epub ahead of print].
38. Li L, Hölscher C. Common pathological processes in Alzheimer's disease and type 2 diabetes: a review. Brain Res Rev 2007, 56:384-402..
39. D'Amico M, Di Filippo C, Marfella R. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010, 45:202-207..
40. Gault VA, Porter WD, Flatt PR, Holscher C. Int J Obes 2010, 34:1341-1344. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet., (Lond)
41. Nathan Y, Lee S, Ashoor G. Restitution of brain responses to food stimuli and feeding in Type 2 diabetes by GLP-1 receptor agonist exenatide. Diabetic Med 2010, 27(Suppl. 1):2..